ITW: This Biotech Startup wants to fix Youth Blindness with a Gene Therapy

18/04/2016 - 6 minutes

While on a stop in New York, I had a chance to chat with Bernard Gilly, the founder and CEO of the Paris biotech GenSight

gensight_LHON_blondness_gene_therapy_biologic_bernard_gilly_biotech_interviewI wanted to learn more about the company, which is one of the only examples in the World using Gene therapy to treat specific and rare types of blindness.

GenSight is interesting in many ways. It was founded very recently (2012) and has since raised a total of €52M in series A & B rounds from some really top-notch VCs: Versant Ventures, Abingworth & Index Ventures (now Medixci).

Bernard Gilly is a veteran of the Biotech space, and even more so in the ophthalmology field. He founded Fovea Pharmaceuticals in 2009, which he sold to Sanofi’s Vision Institute.

He also co-founded the French Pixium Vision (read our take on it here). He has a deep understanding of the field and a extensive experience in entrepreneurship and financing.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member